Source-grounded facts extracted from Nuvation Bio Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Nuvation Bio Inc. reported first quarter ended March 31, 2026 results: revenue $18.5 million.
“Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI”
Nuvation Bio Inc. entered into License Agreement with Eisai Co., Ltd. valued at €50 million (effective 2026-01-11).
“On January 11, 2026, Nuvation Bio Inc. (the “Company”) entered into a License and Collaboration Agreement (the “License Agreement”) with Eisai Co., Ltd. (“Eisai”).”
Jerry Wang resigned as Member of the Board of Directors at Nuvation Bio Inc..
“Additionally, on February 11, 2025, Dr. Wang notified the board of directors (the “Board”) of his resignation as a member of the Board, effective February 11, 2025.”
Jerry Wang departed as Chief Executive Officer of AnHeart Therapeutics at Nuvation Bio Inc..
“On February 12, 2025, Dr. Jerry Wang, the Chief Executive Officer of AnHeart Therapeutics, a Nuvation Bio Inc. (the “Company”) company, departed the Company following the achievement of key Company goals”
Philippe Sauvage was appointed as Chief Financial Officer at Nuvation Bio Inc..
“Effective October 7, 2024 (the “Appointment Date”), the Board of Nuvation Bio Inc. (the “Company”) appointed Philippe Sauvage as the Company’s Chief Financial Officer and Principal Financial Officer.”
Nuvation Bio Inc. reported the first quarter ended March 31, 2024 results: net income $14.8 million, EPS $(0.07) per share.
“For the three months ended March 31, 2024, Nuvation Bio reported a net loss of $14.8 million, or $(0.07) per share.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.